Reimagining Medicine

Company overview Financial review Innovation: Pipeline overview 2023 priorities Appendix Innovation: Clinical trials Abbreviations Our pipeline projects at a glance Innovative Medicines Solid Tumors Hematology Immunology Neuroscience Cardiovascular Others Ophthalmology Respiratory & Allergy Global Health Biosimilars¹ 1. Selected disclosed, internal projects. 52 Investor Relations | Q4 2022 Results Phase 1/2 Phase 3 Registration Total 100 42 8 150 24 15 3 42 21 8 0 29 23 7 4 34 5 LO 5 0 10 8 19 52 5 1 14 2 0 21 5 1 0 6 3 0 0 3 11 1 0 12 0 2 0 2 Total 100 44 8 152 1 NOVARTIS | Reimagining Medicine

View entire presentation